KANSAS CITY, Kan. - eTradeWire -- Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), and Oread Rx, LLC, announce a relationship to supply OTULFI™, a biosimilar of STELARA® to customers in April 2025. As a leader in pharmacy benefits, Oread Rx is committed to delivering exceptional value to both patients and health plans, with a focus on transparency and cost savings.

"Oread Rx is dedicated to sourcing medications at the lowest net cost for patients and health plans. Our relationship with Mark Cuban Cost Plus Drug Company, PBC demonstrates our commitment to act in our client's best interest", said Matt Morrison, PharmD, Chief Executive Officer of Oread Rx. "When medications are affordable, health outcomes improve".

OTULFI™, is available through Cost Plus Drugs, offering nearly 90% annual savings compared to its reference product, STELARA®. Biosimilars, like OTULFI™, offer patients the same clinical benefit as their reference biologics, providing a safe and effective treatment option at a fraction of the cost. The FDA rigorously reviews biosimilars to ensure that they are as safe and effective as the reference product, with no clinically meaningful differences. This provides patients with peace of mind, knowing that they are receiving a high-quality alternative.

More on eTradeWire News

• Merry Christmas 2025 by Rob McConnell Orchestra & Singers Released
• Siembra Brings 18 Latinx Artists Together in Brooklyn Exhibition
• 3 AI Trading Tools Try 14 Days Free – Up to 89% Historical Win Rate
• From "Cherry Pie" to Changed by Grace: Bobbie Jean Brown Shares Her Story of Faith & Redemption
• Rock icon Bobbie Jean Brown returns to the stage now bringing faith, fun & star power to live events

"As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn't afford them," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. "I founded Cost Plus Drugs to help solve this problem and provide a way for patients to receive their medication at an affordable price. We already offer transparent, low prices to cash-pay consumers and are excited to now be working with Oread Rx to further reduce the cost to patients, and to keep the patient record complete from both a clinical and financial perspective."

OREAD RX, LLC

Oread Rx is a pharmacist-owned pharmacy benefit manager (PBM) committed to transforming the pharmacy benefits industry. At the heart of Oread Rx is a dedication to full transparency—ensuring that plan sponsors, payors, patients, and pharmacies can make informed decisions with complete confidence. Through data-driven analytics, responsible payment models, and a focus on improving patient outcomes, Oread Rx is leading the charge in redefining what it means to deliver value in healthcare. To learn more, visit oreadrx.com.

More on eTradeWire News

• XRP ETF Breakthrough: New Book Explains the Math Behind the Expected Supply Squeeze
• Prescott Area Habitat for Humanity to Celebrate 100th Family Home Dedication
• GenieChat Announces Free Plan, Positioning Itself as the Seller-First Alternative to Boards
• Gramercy Tech Launches StoryStream
• PixelPulse Fashion Launches Black Friday Mega Sales with Up to 50% Off Anime and Gaming Styles

MARK CUBAN COST PLUS DRUG COMPANY

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,500 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide.

For additional Safety Information, please talk to your doctor and click for OTULFI™, Full Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761379s001lbl.pdf or https://www.fresenius-kabi.com